Avandia Concerns Highlight Need To Change Diabetes Approval Standards

FDA should forgo use of glycemic control as a surrogate endpoint for clinical trials supporting the approval of type 2 diabetes therapies, Clifford Rosen said following the advisory committee review of GlaxoSmithKline's Avandia

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet